Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Atreca Stock (NASDAQ: BCEL) stock price, news, charts, stock research, profile.
Open0.280 | Close- |
Vol / Avg.11.403K / 198.720K | Mkt Cap11.435M |
Day Range0.280 - 0.291 | 52 Wk Range0.255 - 2.050 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.570 | -0.490 | 0.0800 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-14 | Wedbush | Robert Driscoll | Downgrades | OutperformNeutral | Lowers | 4.00 | 1.00 |
2023-08-11 | Stifel | Stephen Willey | Downgrades | BuyHold | Lowers | 4.00 | 1.00 |
2023-08-11 | HC Wainwright & Co. | Joseph Pantginis | Downgrades | BuyNeutral | - | - | - |
2023-06-05 | HC Wainwright & Co. | Joseph Pantginis | Reiterates | BuyBuy | Maintains | - | 25.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
BCEL | Atreca | 11.92% | 11.4M |
ERNA | Eterna Therapeutics | -1.91% | 11.1M |
IMPL | Impel Pharmaceuticals | 2.82% | 13.2M |
IMRN | Immuron | -1% | 11.2M |
DOMH | Dominari Holdings | 2.13% | 12.7M |
You can purchase shares of Atreca (NASDAQ: BCEL) through any online brokerage.
Other companies in Atreca’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Impel Pharmaceuticals (NASDAQ:IMPL), Immuron (NASDAQ:IMRN), Dominari Holdings (NASDAQ:DOMH) and Comera Life Sciences (NASDAQ:CMRA).
The latest price target for Atreca (NASDAQ: BCEL) was reported by Wedbush on Monday, August 14, 2023. The analyst firm set a price target for 1.00 expecting BCEL to rise to within 12 months (a possible 243.64% upside). 13 analyst firms have reported ratings in the last year.
The stock price for Atreca (NASDAQ: BCEL) is $0.291 last updated Today at September 27, 2023 at 2:11 PM UTC.
There is no dividend information for Atreca.
Atreca’s Q3 earnings are confirmed for Thursday, November 9, 2023.
There is no upcoming split for Atreca.
Atreca is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.